{"doi":"10.1152/physrev.00001.2019","title":"Methylglyoxal, a Highly Reactive Dicarbonyl Compound, in Diabetes, Its Vascular Complications, and Other Age-Related Diseases","abstract":"<jats:p>The formation and accumulation of methylglyoxal (MGO), a highly reactive dicarbonyl compound, has been implicated in the pathogenesis of type 2 diabetes, vascular complications of diabetes, and several other age-related chronic inflammatory diseases such as cardiovascular disease, cancer, and disorders of the central nervous system. MGO is mainly formed as a byproduct of glycolysis and, under physiological circumstances, detoxified by the glyoxalase system. MGO is the major precursor of nonenzymatic glycation of proteins and DNA, subsequently leading to the formation of advanced glycation end products (AGEs). MGO and MGO-derived AGEs can impact on organs and tissues affecting their functions and structure. In this review we summarize the formation of MGO, the detoxification of MGO by the glyoxalase system, and the biochemical pathways through which MGO is linked to the development of diabetes, vascular complications of diabetes, and other age-related diseases. Although interventions to treat MGO-associated complications are not yet available in the clinical setting, several strategies to lower MGO have been developed over the years. We will summarize several new directions to target MGO stress including glyoxalase inducers and MGO scavengers. Targeting MGO burden may provide new therapeutic applications to mitigate diseases in which MGO plays a crucial role.</jats:p>","journal":"Physiological Reviews","year":2020,"id":623570,"datarank":8.570676585710336,"base_score":6.406879986069314,"endowment":6.406879986069314,"self_citation_contribution":0.9610319979103973,"citation_network_contribution":7.609644587799938,"self_endowment_contribution":0.9610319979103973,"citer_contribution":7.609644587799938,"corpus_percentile":null,"corpus_rank":null,"citation_count":605,"citer_count":200,"citers_with_citation_signal":200,"citers_with_endowment":200,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1611584,"name":"C. D. A. Stehouwer","orcid":null,"position":1,"is_corresponding":false},{"id":1611581,"name":"C. G. Schalkwijk","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Methylglyoxal, a Highly Reactive Dicarbonyl Compound, in Diabetes, Its Vascular Complications, and Other Age-Related Diseases","abstract":"<jats:p>The formation and accumulation of methylglyoxal (MGO), a highly reactive dicarbonyl compound, has been implicated in the pathogenesis of type 2 diabetes, vascular complications of diabetes, and several other age-related chronic inflammatory diseases such as cardiovascular disease, cancer, and disorders of the central nervous system. MGO is mainly formed as a byproduct of glycolysis and, under physiological circumstances, detoxified by the glyoxalase system. MGO is the major precursor of nonenzymatic glycation of proteins and DNA, subsequently leading to the formation of advanced glycation end products (AGEs). MGO and MGO-derived AGEs can impact on organs and tissues affecting their functions and structure. In this review we summarize the formation of MGO, the detoxification of MGO by the glyoxalase system, and the biochemical pathways through which MGO is linked to the development of diabetes, vascular complications of diabetes, and other age-related diseases. Although interventions to treat MGO-associated complications are not yet available in the clinical setting, several strategies to lower MGO have been developed over the years. We will summarize several new directions to target MGO stress including glyoxalase inducers and MGO scavengers. Targeting MGO burden may provide new therapeutic applications to mitigate diseases in which MGO plays a crucial role.</jats:p>","is_dataset_classified":null,"base_score":6.406879986069314,"endowment":6.406879986069314,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"31539311","pmcid":null,"openalex_id":"https://openalex.org/W2973932371","authors":[],"funders":[{"funder_name":"Netherlands Organisation for Health Research and Development","grant_id":"91118005","title":null},{"funder_name":"Netherlands Organisation for Health Research and Development","grant_id":"95105002","title":null},{"funder_name":"Diabetes Fonds","grant_id":"","title":null},{"funder_name":"European Foundation for the Study of Diabetes","grant_id":"","title":null}],"total_grants":4,"fwci":29.0161,"citation_percentile":0.99923166,"influential_citations":0,"citation_trend":[{"year":2019,"count":1},{"year":2020,"count":42},{"year":2021,"count":70},{"year":2022,"count":95},{"year":2023,"count":98},{"year":2024,"count":105},{"year":2025,"count":122},{"year":2026,"count":72}],"oa_status":"green","license":"other-oa","oa_locations":[{"url":"https://cris.maastrichtuniversity.nl/en/publications/301b39e4-80e5-4139-9ebd-8b98abae7eb9","host_type":"repository"},{"url":"https://cris.maastrichtuniversity.nl/en/publications/301b39e4-80e5-4139-9ebd-8b98abae7eb9","host_type":"repository"},{"url":"https://journals.physiology.org/doi/pdf/10.1152/physrev.00001.2019","host_type":"publisher"},{"url":"https://doi.org/10.1152/physrev.00001.2019","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/31539311","host_type":"repository"}],"fields_of_study":["Advanced Glycation End Products research","Parkinson's Disease Mechanisms and Treatments","Alcohol Consumption and Health Effects"],"mesh_terms":["Hydroxyacylglutathione Hydrolase","Animals","Cardiovascular Diseases","Diabetes Mellitus, Type 2","Humans","Lactoylglutathione Lyase","Neoplasms","Pyruvaldehyde","Thiolester Hydrolases"],"keywords":["Methylglyoxal","Glycation","Diabetes mellitus","Lactoylglutathione lyase","Oxidative stress","Medicine","Advanced glycation end-product","Disease","Pathogenesis","Glycolysis","Internal medicine","Endocrinology","Chemistry","Pharmacology","Biochemistry","Bioinformatics","Biology","Metabolism","Enzyme","Obesity","Ageing","Type 2 diabetes mellitus","advanced glycation end products","Glyoxalase"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T00:23:42.718079Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}